Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks

NCT02582996 is registered in ClinicalTrials.gov with Ache Laboratorios Farmaceuticos S.A. as lead sponsor.

NCT NCT02582996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02582996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Phase
Phase 3
Overall status
Suspended
Start date
April 30, 2020
Completion date
June 30, 2021
Enrollment
336 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

migraine